BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting the translation initiator EIF4A1 and the glutamine metabolism enzyme GLS could treat pancreatic ductal adenocarcinoma (PDAC). An EIF4A1 inhibitor tool compound lowered the viability of mouse PDAC organoids...
BC Extra | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the...
BC Innovations | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
BC Extra | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
BC Week In Review | Feb 2, 2018
Clinical News

Effector reports Phase I/II data for eFT508 in hematological malignancies

Effector Therapeutics Inc. (San Diego, Calif.) reported data from 10 evaluable patients with hematological malignancies in a Phase I/II trial showing that eFT508 led to one partial response in a patient with non-germinal center B...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Week In Review | Nov 3, 2017
Clinical News

Effector begins Phase II trial of eFT508 plus Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635) to treat microsatellite stable colorectal cancer (CRC). Part one of the open-label, U.S....
BC Innovations | Aug 9, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the MKNK1 - MKNK2 - eIF4E axis could help treat pain. In a mouse model of inflammatory pain, knock-in of an elF4E variant that cannot be phosphorylated by MKNK1 or MKNK2...
Items per page:
1 - 10 of 37
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting the translation initiator EIF4A1 and the glutamine metabolism enzyme GLS could treat pancreatic ductal adenocarcinoma (PDAC). An EIF4A1 inhibitor tool compound lowered the viability of mouse PDAC organoids...
BC Extra | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the...
BC Innovations | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
BC Extra | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
BC Week In Review | Feb 2, 2018
Clinical News

Effector reports Phase I/II data for eFT508 in hematological malignancies

Effector Therapeutics Inc. (San Diego, Calif.) reported data from 10 evaluable patients with hematological malignancies in a Phase I/II trial showing that eFT508 led to one partial response in a patient with non-germinal center B...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Week In Review | Nov 3, 2017
Clinical News

Effector begins Phase II trial of eFT508 plus Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635) to treat microsatellite stable colorectal cancer (CRC). Part one of the open-label, U.S....
BC Innovations | Aug 9, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the MKNK1 - MKNK2 - eIF4E axis could help treat pain. In a mouse model of inflammatory pain, knock-in of an elF4E variant that cannot be phosphorylated by MKNK1 or MKNK2...
Items per page:
1 - 10 of 37